Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

2.

Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins.

Bernard ME, Sutera PA, Iarrobino NA, Quan K, Burton SA, Bahary N, Hogg M, Zureikat A, Heron DE.

Adv Radiat Oncol. 2018 Nov 29;4(2):294-301. doi: 10.1016/j.adro.2018.11.007. eCollection 2019 Apr-Jun.

3.

Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?

Ling DC, Sutera PA, Iarrobino NA, Diego EJ, Soran A, Johnson RR, Bhargava R, Champ CE, Beriwal S.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):869-876. doi: 10.1016/j.ijrobp.2019.03.012. Epub 2019 Mar 15.

PMID:
30885777
4.

Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma.

Sutera PA, Bernard ME, Wang H, Heron DE.

Front Oncol. 2018 Jul 27;8:282. doi: 10.3389/fonc.2018.00282. eCollection 2018.

5.

Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.

Premkumar DR, Jane EP, Thambireddy S, Sutera PA, Cavaleri JM, Pollack IF.

Mol Carcinog. 2018 Apr;57(4):469-482. doi: 10.1002/mc.22771. Epub 2017 Dec 30.

6.

Salvage stereotactic radiosurgery for recurrent gliomas with prior radiation therapy.

Sutera PA, Bernard ME, Gill BS, Quan K, Engh JA, Burton SA, Heron DE.

Future Oncol. 2017 Dec;13(29):2681-2690. doi: 10.2217/fon-2017-0226. Epub 2017 Dec 4.

PMID:
29198146
7.

One- vs. Three-Fraction Pancreatic Stereotactic Body Radiation Therapy for Pancreatic Carcinoma: Single Institution Retrospective Review.

Sutera PA, Bernard ME, Gill BS, Harper KK, Quan K, Bahary N, Burton SA, Zeh H, Heron DE.

Front Oncol. 2017 Nov 14;7:272. doi: 10.3389/fonc.2017.00272. eCollection 2017.

8.

Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.

Jane EP, Premkumar DR, Sutera PA, Cavaleri JM, Pollack IF.

Mol Carcinog. 2017 Apr;56(4):1251-1265. doi: 10.1002/mc.22587. Epub 2016 Nov 22.

9.

Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.

Jane EP, Premkumar DR, Cavaleri JM, Sutera PA, Rajasekar T, Pollack IF.

J Pharmacol Exp Ther. 2016 Feb;356(2):354-65. doi: 10.1124/jpet.115.230052. Epub 2015 Nov 19.

10.

Enzymatic C(sp3)-H Amination: P450-Catalyzed Conversion of Carbonazidates into Oxazolidinones.

Singh R, Kolev JN, Sutera PA, Fasan R.

ACS Catal. 2015 Mar 6;5(3):1685-1691. Epub 2015 Jan 29.

Supplemental Content

Loading ...
Support Center